EMERYVILLE, Calif.--(BUSINESS WIRE)--Octant, Inc., a synthetic biology drug discovery company designing small molecule, multi-target drug leads for multifactorial diseases announced that it has raised ...

Octant Bio set out on a journey to show that the convergence of synthetic biology, chemistry, and computational techniques could lead to new drugs for patients. That destination is still distant, but ...

Many of today’s most trusted drugs are so notorious for their wide range of potentially serious adverse reactions, they are known in the business as “dirty drugs.” Synthetic biology company Octant Bio ...

EMERYVILLE, Calif., May 26, 2022 (GLOBE NEWSWIRE) -- Zymergen Inc. (“Zymergen” or the “Company”), today announced it has entered into an agreement with Octant for the sale of a modular automation ...

“We have been working with Mark for over a year as a Board Member and are thrilled to share that he’s now working with us day-to-day,” said Sri Kosuri, CEO of Octant. “Mark’s unique experience and ...

Octant, a company backed by Andreessen Horowitz just now unveiling itself publicly to the world, is using the tools of synthetic biology to buck the latest trends in drug discovery. As the ...